Oral factor Xa inhibitors in acute coronary syndromes

Luke Tapp, Ben Wrigley, Gregory Lip

Research output: Contribution to journalEditorial

1 Citation (Scopus)


Factor Xa inhibitors, a new class of oral anticoagulants, have been evaluated in the phase II ATLAS ACS-TIMI 46 and APPRAISE trials. addition of these agents to standard therapy has tended to reduce the incidence of adverse cardiovascular events at the expense of a dose-dependent increase in the risk of bleeding complications.
Original languageEnglish
Pages (from-to)619-620
Number of pages2
JournalNature Reviews Cardiology
Issue number10
Publication statusPublished - 1 Oct 2009


Dive into the research topics of 'Oral factor Xa inhibitors in acute coronary syndromes'. Together they form a unique fingerprint.

Cite this